

**IN THE CLAIMS**

Please amend claims 22, 26 and 28 to read as follows:

B8  
22. (amended) A method for treating Hepatitis B virus (HBV) infection or inhibiting HBV virus replication comprising administering to an HBV-infected patient a compound that modulates the level of cytosolic calcium, in an amount effective to inhibit HBV replication.

B9  
26. (amended) The method of claim 24 wherein the compound inhibits or interferes with the activity of an endoplasmic reticulum calcium channel.

B10  
28. (amended) The method of claim 24 wherein the compound is 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetate (BAPTA) or bis-(o-aminophenyl)ethyleneglycol-N,N,N',N'-tetraacetic acid (BAPTA-AM).

**REMARKS**

Applicants note with appreciation that the Examiner has found the claimed invention free of the prior art.

The specification has been amended to correct minor typographical errors and to include the full name of compounds that had been abbreviated in the specification as filed (e.g., BAPTA and BAPTA-AM). The corrections introduce no new matter.

Claims 22-30 are pending. Claims 22, 26 and 28 have been amended. Claim 22 has been amended to more particularly point out and distinctly claim the invention. Support for amended claim 22 is found on page 11, lines 1-10 and on page 45, lines 2-8 of the instant specification. Claim 26 has been amended to correct a typographical error. Claim 28 has been amended as suggested by the Examiner to spell out the full description of "BAPTA." Support for amended claim 28 is found on page 7, lines 15-20 and on page 27, lines 8-29 of the instant specification. The claim amendments do not introduce new matter.

A marked up version of the amended paragraphs and claims showing the amendments is attached hereto as Appendix A and B, respectively. Matter that has been deleted is indicated by brackets and matter that has been added is indicated by underlining. A copy of the claims as pending after entry of the foregoing amendment is attached as